Natalizumab for induction of remission in Crohn's disease
about
Mapping early conformational changes in alphaIIb and beta3 during biogenesis reveals a potential mechanism for alphaIIbbeta3 adopting its bent conformation.Hypoxia and hypoxia mimetics inhibit TNF-dependent VCAM1 induction in the 5A32 endothelial cell line via a hypoxia inducible factor dependent mechanism.Integrins as Therapeutic Targets: Successes and Cancers.
P2860
Natalizumab for induction of remission in Crohn's disease
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Natalizumab for induction of remission in Crohn's disease
@ast
Natalizumab for induction of remission in Crohn's disease
@en
Natalizumab for induction of remission in Crohn's disease
@en-gb
Natalizumab for induction of remission in Crohn's disease
@nl
type
label
Natalizumab for induction of remission in Crohn's disease
@ast
Natalizumab for induction of remission in Crohn's disease
@en
Natalizumab for induction of remission in Crohn's disease
@en-gb
Natalizumab for induction of remission in Crohn's disease
@nl
prefLabel
Natalizumab for induction of remission in Crohn's disease
@ast
Natalizumab for induction of remission in Crohn's disease
@en
Natalizumab for induction of remission in Crohn's disease
@en-gb
Natalizumab for induction of remission in Crohn's disease
@nl
P2860
P1476
Natalizumab for induction of remission in Crohn's disease
@en
P2093
JK MacDonald
JWD McDonald
P2860
P356
10.1002/14651858.CD006097
P577
2006-07-19T00:00:00Z